AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01714700 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard diet, Resistance exercise
Description: The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
Study NCT00617240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
Study NCT00617240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
Study NCT04870840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo radiation therapy
Study NCT04870840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04870840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04537715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
Study NCT04537715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral 200 mg itraconazole once daily on Days 18 - 38
Study NCT04537715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
Study NCT04537715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral 600 mg rifampin once daily on Days 17 - 25.
Study NCT02342574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study NCT04563312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Nine different clubs and sport centers were screened and 18- to 35-year-old individuals regularly engaged in MT or BB for the last 6 months were invited to join the study.
Study NCT02418338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speckle tracking (2D strain) echocardiography
Description: 2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
Study NCT02418338 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: speckle tracking (2D strain) echocardiography
Description: 2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
Study NCT03562923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
Study NCT03562923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
Study NCT03562923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Product
Study NCT05645263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dieting Coca-cola
Description: The patients all dieted Coco-cola to treat gastric phytobezoars, 250ml-500ml/2 h till to sleeping time according to the health conditions and life habits. Pay more attention to the stools and assess if the bezoars had excreted. The dieting Coco-cola period of group A is 3 days, group B is 5 days and group C is 7 days.
Study NCT02716519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Santyl
Description: Collagenase ointment applied topically once per day for up to six weeks
Study NCT02716519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
Study NCT01578603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: 6 g/day, for a month, by chewing 2g three times daily after meals.
Study NCT01578603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: casein phosphopeptide amorphous calcium phosphate complex
Description: two pieces of the commercial presentation three times daily after meals
Study NCT00433771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WallFlex™ Biliary Fully Covered Metal Stent placement
Description: Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
Study NCT00605839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoPak
Description: We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
Study NCT00605839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell Phone
Description: We will provide cell phones and access to the clinic to facilitate communications
Study NCT00605839 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: This intervention was usual care, without either device.
Study NCT03491800 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Question/Topic Prompt List
Description: A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: antineoplastic enzyme inhibitor
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: antineoplastic enzyme inhibitor
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin D
Description: Antineoplastic agent that is a polypeptide antibiotic
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinomycin D
Description: Antineoplastic agent that is a polypeptide antibiotic
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: An anthracycline topoisomerase inhibitor isolated from streptpmyces peucetius var. casesius
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: chemotherapeutic agent chemically related to the nitrogen mustards and is a synthetic analog of cyclophosphamide
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: anti neoplastic vinca alkaloid agent
Study NCT01294995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea-flavor Liquor
Description: 30 mL of Tea-flavor Liquor(45% alcohol content)
Study NCT01294995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Guizhou Meijiao Liquor
Description: 30 mL of Guizhou Meijiao Liquor (45% alcohol content)
Study NCT02052739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547
Description: Solution for injection for IV infusion
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: vinca alkaloid with a role as an antineoplastic agent
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: oral antineoplastic alkylating agent
Study NCT04625907 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Ionising radiation
Study NCT04625907 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Ionising radiation
Study NCT04625907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral multi-kinase inhibitor that targets a broad range of angiogenic, stromal and oncogenic kinases, including vascular endothelial growth factor receptors (VEFGR) 1, 2 and 3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 (TIE2), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), c-KIT, RET, RAF-1 and BRAF (wild-type and V600E mutant).
Study NCT00602927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
Study NCT00602927 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
Study NCT01365741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upright position
Description: The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
Study NCT00499252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Study NCT01974869 — intervention group
Intervention type: DRUG
Intervention: Anti-tumor necrosis factor alpha agents
Description: Treatment with biologics
Study NCT00535873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
Study NCT02973178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scanadu Urine Device
Description: Device to allow lay user to perform urinalysis test at home.
Study NCT02973178 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Scanadu Urine Device
Description: Device to allow lay user to perform urinalysis test at home.
Study NCT03476837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample and WCG's carbon monoxide. Saliva samples will be collect from one child in the home at baseline and final. Baseline saliva data and carbon monoxide monitoring will be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
Study NCT03476837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
Study NCT01982045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AttraX® Putty
Description: Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
Study NCT01982045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
Study NCT02416089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampostat
Study NCT02416089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condom catheter tamponade
Study NCT03217474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLDEB
Description: The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
Study NCT03217474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV)
Description: Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
Study NCT03217474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir (GCV)
Description: Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
Study NCT03217474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond laser
Description: A commercial femtosecond laser to create a particular shaped graft for transplantation.
Study NCT02188927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of ANL
Description: Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
Study NCT02188927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No included ANL
Description: Sending Standard Invitation only six weeks before planned screening colonoscopy
Study NCT01655173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Description: The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session.
Study NCT01655173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recreational activity intervention
Description: The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
Study NCT01591499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOFINITY® MF - AIR OPTIX® AQUA MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
Study NCT01591499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOFINITY® MF - AIR OPTIX® AQUA MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
Study NCT01591499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOFINITY® MF - PUREVISION® MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
Study NCT01591499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOFINITY® MF - PUREVISION® MF
Description: During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
Study NCT04288739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: flow cytometric immunophenotyping
Description: Flow cytometric (FCM) immunophenotypic analysis of peripheral blood or bone marrow aspiration samples will be performed using a panel of monoclonal antibodies (HLA DR, CD34, CD117, Cyto MPO, CD13, CD33, CD3, CD4, CD8, CD10, CD19, CD5, CD14, CD64, CD36, CD235a, cyto CD41, cyto CD61).
Study NCT04288739 — intervention group
Intervention type: GENETIC
Intervention: Xist gene by fluorescence insitu hybridization
Description: Fluorescence in situ hybridization (FISH) is a kind of cytogenetic technique that allows the visualization of defined nucleic acid sequences in particular cellular or chromosomal sites by hybridization of complementary fluorescently labeled probe sequences within intact metaphase or interphase cells.~The fluorescent probes are nucleic acid labeled with fluorescent groups and can bind to specific DNA/RNA sequences. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes.
Study NCT01256086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formatris 24µg
Description: 12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
Study NCT01256086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formatris 12µg
Description: 12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
Study NCT01256086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil P 24µg
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
Study NCT01256086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foradil P 12µg
Description: Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
Study NCT03037918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult light
Description: A fermented milk drink containing the probiotic Lactobacillus casei Shirota
Study NCT02204449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Peer Mentorship
Study NCT01912547 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw for TEG analysis
Description: Blood drawn for TEG analysis
Study NCT01556464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-adjusting CPAP
Description: A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
Study NCT00422916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Study NCT01269918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
Study NCT03190707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 1. Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~2. Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~3. Strengthen parenting skills through:~   * Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~  * Teaching the woman/couple on the importance of breast-feeding and how to succeed.
Study NCT04450316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 4.5mg tab (low-dose) nightly
Study NCT01269918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
Study NCT00544596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-(-)-gossypol acetic acid
Description: Given orally